---
type: "Nootropic"
title: "Oxiracetam"
description: "Oxiracetam is a synthetic racetam. Post-stroke prevention and acute traumatic-brain-injury studies concern different patients, products and routes; they do not establish cognitive benefits or personal-use protocols for healthy people."
resource: "https://nootropikler.com/nootropics/oxiracetam"
tags: ["racetam", "synthetic"]
timestamp: 2026-11-11T00:00:00Z
category: "cognitive"
source: "synthetic"
latin: "4-hydroxy-2-oxo-1-pyrrolidineacetamide"
language: "en"
---

# Oxiracetam

*4-hydroxy-2-oxo-1-pyrrolidineacetamide*

Oxiracetam is a synthetic racetam. Post-stroke prevention and acute traumatic-brain-injury studies concern different patients, products and routes; they do not establish cognitive benefits or personal-use protocols for healthy people.

## Quick profile

| Property | Value |
| --- | --- |
| Onset of Effect | No established timeframe |
| Dose used in research | No established dose for cognitive use |
| with choline | Requirement not established |
| Safety | See detailed safety warnings |

> 2026-11-11 correction: The 2026 stroke trial, 2025 L-oxiracetam trial and 2026 trauma meta-analysis were assessed separately. Renal-function-dependent elimination was distinguished from a general 8-hour value. Unverified synergy, adverse-event frequencies and meal advice were removed.

## What is Oxiracetam?

Oxiracetam is a synthetic racetam. Post-stroke prevention and acute traumatic-brain-injury studies concern different patients, products and routes; they do not establish cognitive benefits or personal-use protocols for healthy people.

## Mechanism of Effect

Pavlík et al. (1987) reported increased hippocampal high-affinity choline uptake (HACU) after 6 days of pramiracetam or oxiracetam in male rats; striatal dopamine and HVA were unchanged.

This is an animal biochemical finding; it does not demonstrate human memory enhancement, choline deficiency or a need for choline supplementation. HACU measurement is not evidence of clinical efficacy or safe drug combinations.

## Clinical Evidence

Lim et al. (2026) reported a 36-week placebo-controlled trial in 500 high-risk post-stroke participants; 457 completed it. Oxiracetam was not superior in changes in MMSE or CDR-SB (p=0.49 and p=0.38).

The primary outcomes did not support benefit in this selected stroke population. Physical activity was not randomized; exploratory subgroup or imaging signals cannot be converted into proven synergy or clinical prevention.

Liu et al. (2025) compared 14 days of intravenous L-oxiracetam, oxiracetam and placebo in 590 patients with traumatic brain injury. Day-90 LOTCA changes were 20.45, 15.90 and 11.47 respectively; the adjusted L-oxiracetam versus placebo difference was 8.97 points (95% CI 5.69–12.26).

This inpatient trial studied distinct enantiomer and intravenous products, not oral use in healthy people. Before the day-90 assessment, 146 participants withdrew; the LOTCA result does not establish benefit on every secondary measure or long-term safety.

Wang et al. (2026) synthesized 33 randomized trials (2864 participants) in acute traumatic brain injury. In 10 trials with balanced background therapy (798 participants), the post-treatment MMSE difference was 4.67 points (95% CI 3.07–6.28; I²=92%).

This is a difference between post-treatment group means, not an individual’s change from baseline. Evidence certainty is low or very low; heterogeneity, risk of bias and incomplete harm reporting preclude conclusions about durable benefit, routine use or safe doses.

## Dose information and research limits

Lecaillon et al. (1990) found plasma half-lives of 10.6–68.1 hours after a single oral 800 mg dose of oxiracetam in 20 patients with varying renal function; elimination was slower with greater renal impairment.

This wide patient range is not a fixed half-life or dose-adjustment formula for healthy people. A general 8-hour value cannot calculate personal accumulation, medication timing or treatment of kidney disease.

> **Dose information and research limits:** This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

## Safety and Side Effects

Oxiracetam elimination varies with renal function. Limited or incomplete adverse-event reporting in trauma studies does not establish long-term or drug-combination safety; do not change prescribed treatment on your own.

The FDA’s 2019 Peak Nootropics warning letter addresses marketed treatment claims for aniracetam, oxiracetam and pramiracetam products; it does not recognize those products as approved safe and effective treatments.

This is a dated US regulatory record about the named seller and claims; it is not a current global approval map or a clinical experiment measuring a particular adverse-event rate. Online sale does not establish safety or approval.


## Frequently Asked Questions

### What is Oxiracetam and what does it do?

Oxiracetam is a synthetic racetam. Post-stroke prevention and acute traumatic-brain-injury studies concern different patients, products and routes; they do not establish cognitive benefits or personal-use protocols for healthy people.

### How much should the Oxiracetam dosage be?

The amounts below are research or use examples, not established cognitive treatment doses for healthy people. Controlled human trials have not established that choline supplementation is mandatory with racetams or prevents headaches.

### When should Oxiracetam be taken?

This wide patient range is not a fixed half-life or dose-adjustment formula for healthy people. A general 8-hour value cannot calculate personal accumulation, medication timing or treatment of kidney disease.

### Is Oxiracetam legal in Türkiye?

Sale and import status in Türkiye must be checked for the specific product. Verify supplement approval in the Ministry of Agriculture and Forestry GGBS list, and medicine authorization and conditions of use in TİTCK records. Online availability does not establish approval or unrestricted personal import; current Ministry of Trade conditions apply to postal and express shipments.

### What is the difference between oxiracetam and piracetam?

This is a difference between post-treatment group means, not an individual’s change from baseline. Evidence certainty is low or very low; heterogeneity, risk of bias and incomplete harm reporting preclude conclusions about durable benefit, routine use or safe doses.

## Sources

- Gouliaev, A.H., Senning, A. (1994). Piracetam and other structurally related nootropics. *Brain Research Reviews*, 19(2), 180–222. [PubMed · PMID 8061686](https://pubmed.ncbi.nlm.nih.gov/8061686/)
- Itil TM, Menon GN, Bozak M, Songar A. (1982). The effects of oxiracetam (ISF 2522) in patients with organic brain syndrome (a double-blind controlled study with piracetam). *Drug Development Research*, 2(5), 447–461. https://doi.org/10.1002/ddr.430020506 [Publisher record · DOI · Wiley](https://doi.org/10.1002/ddr.430020506)
- Malykh, A.G., Sadaie, M.R. (2010). Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. *Drugs*, 70(3), 287–312. [PubMed · PMID 20166767](https://pubmed.ncbi.nlm.nih.gov/20166767/)
- Lecaillon JB, et al. (1990). Pharmacokinetics of oxiracetam in patients with renal impairment after a 800 mg single oral dose. *European Journal of Drug Metabolism and Pharmacokinetics*, 15(3), 231–7. https://doi.org/10.1007/BF03190209 [PubMed · PMID 2253654](https://pubmed.ncbi.nlm.nih.gov/2253654/)
- Lim JS, et al. (2026). Oxiracetam and physical activity in preventing cognitive decline after stroke: A multicenter, randomized controlled trial. *European Stroke Journal*, 11(1), 23969873251350141. https://doi.org/10.1093/esj/23969873251350141 [PubMed · PMID 41614470](https://pubmed.ncbi.nlm.nih.gov/41614470/)
- Liu T, et al. (2025). Efficacy and safety of L-oxiracetam on cognitive function in patients with traumatic brain injury: a multicentre, randomised, double-blind, phase 3 clinical trial. *Signal Transduction and Targeted Therapy*, 10, 401. https://doi.org/10.1038/s41392-025-02492-5 [PubMed · PMID 41381424](https://pubmed.ncbi.nlm.nih.gov/41381424/)
- Pavlík A, Benesová O, Dlohozková N. (1987). Effects of nootropic drugs on brain cholinergic and dopaminergic transmission. *Activitas Nervosa Superior*, 29(1), 62–65. [PubMed · PMID 3035858](https://pubmed.ncbi.nlm.nih.gov/3035858/)
- US Food and Drug Administration. (2019). Warning Letter: Peak Nootropics LLC aka Advanced Nootropics. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-nootropics-llc-aka-advanced-nootropics-557887-02052019 [US Food and Drug Administration](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-nootropics-llc-aka-advanced-nootropics-557887-02052019)
- Wang M, Cao N, Shou Z, Pan J. (2026). Efficacy and safety of oxiracetam for cognitive and functional outcomes after acute traumatic brain injury in Chinese populations: a systematic review and meta-analysis of randomized controlled trials. *Frontiers in Pharmacology*, 17, 1894256. https://doi.org/10.3389/fphar.2026.1894256 [PubMed · PMID 42835276](https://pubmed.ncbi.nlm.nih.gov/42835276/)

## Related nootropics

- [Piracetam](/okf/nootropics/piracetam.md)
- [aniracetam](/okf/nootropics/aniracetam.md)
- [noopept](/okf/nootropics/noopept.md)
- [Alpha-GPC](/okf/nootropics/alpha-gpc.md)
